- Home
- EQX vs MIRM Comparison
EQX vs MIRM Comparison
Compare EQX & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQX
- MIRM
- Stock Information
- Founded
- EQX 2007
- MIRM 2018
- Country
- EQX Canada
- MIRM United States
- Employees
- EQX N/A
- MIRM 334
- Industry
- EQX Precious Metals
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- EQX Basic Materials
- MIRM Health Care
- Exchange
- EQX Nasdaq
- MIRM Nasdaq
- Market Cap
- EQX 2.8B
- MIRM 2.2B
- IPO Year
- EQX N/A
- MIRM 2019
- Fundamental
- Price
- EQX $6.65
- MIRM $44.46
- Analyst Decision
- EQX
- MIRM Strong Buy
- Analyst Count
- EQX 0
- MIRM 12
- Target Price
- EQX N/A
- MIRM $63.17
- AVG Volume (30 Days)
- EQX 12.2M
- MIRM 397.1K
- Earning Date
- EQX 05-07-2025
- MIRM 05-07-2025
- Dividend Yield
- EQX N/A
- MIRM N/A
- EPS Growth
- EQX N/A
- MIRM N/A
- EPS
- EQX 0.64
- MIRM N/A
- Revenue
- EQX $1,696,526,000.00
- MIRM $379,251,000.00
- Revenue This Year
- EQX $40.61
- MIRM $33.98
- Revenue Next Year
- EQX $14.56
- MIRM $16.19
- P/E Ratio
- EQX $9.85
- MIRM N/A
- Revenue Growth
- EQX 54.88
- MIRM 69.31
- 52 Week Low
- EQX $4.48
- MIRM $23.83
- 52 Week High
- EQX $7.45
- MIRM $54.23
- Technical
- Relative Strength Index (RSI)
- EQX 53.47
- MIRM 54.21
- Support Level
- EQX $6.54
- MIRM $43.49
- Resistance Level
- EQX $6.85
- MIRM $44.57
- Average True Range (ATR)
- EQX 0.20
- MIRM 1.19
- MACD
- EQX 0.05
- MIRM -0.09
- Stochastic Oscillator
- EQX 79.50
- MIRM 43.49
About EQX Equinox Gold Corp.
Equinox Gold Corp is a mining company engaged in the operation, acquisition, exploration, and development of mineral properties, with a focus on gold. Equinox Gold has around seven operating gold mines and a clear plan to increase production by advancing the pipeline of growth projects. Geographically, the company operates in the United States, Mexico, and Brazil. The majority of its revenue is generated from Canada.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.